Insider Trading Alert - INSY, RAI And ACGL Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 13, 2014, 133 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $83.06 to $209,607,265.20.

Highlighted Stocks Traded by Insiders:

Insys Therapeutics (INSY) - FREE Research Report

Stanley Theodore H who is Director at Insys Therapeutics bought 500 shares at $72.53 on March 13, 2014. Following this transaction, the Director owned 1,400 shares meaning that the stake was reduced by 55.56% with the 500-share transaction.

The shares most recently traded at $75.79, up $3.26, or 4.3% since the insider transaction. Historical insider transactions for Insys Therapeutics go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 1,262
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 1,262
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 1,262

The average volume for Insys Therapeutics has been 291,500 shares per day over the past 30 days. Insys Therapeutics has a market cap of $1.6 billion and is part of the health care sector and drugs industry. Shares are up 91.11% year-to-date as of the close of trading on Friday.

INSYS Therapeutics, Inc., a development stage company, develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company has a P/E ratio of 35.1. Currently there are 2 analysts that rate Insys Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on INSY - FREE

TheStreet Quant Ratings rates Insys Therapeutics as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Insys Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Reynolds American (RAI) - FREE Research Report

Adams Thomas R who is EVP & Chief Financial Officer at Reynolds American sold 28,221 shares at $53.49 on March 13, 2014. Following this transaction, the EVP & Chief Financial Officer owned 66,671 shares meaning that the stake was reduced by 29.74% with the 28,221-share transaction.

Folan Mcdara who is SVP, Deputy GC & Secretary at Reynolds American sold 9,953 shares at $53.49 on March 13, 2014. Following this transaction, the SVP, Deputy GC & Secretary owned 15,008 shares meaning that the stake was reduced by 39.87% with the 9,953-share transaction.

Fawley Daniel A who is SVP & Treasurer at Reynolds American sold 9,488 shares at $53.48 on March 13, 2014. Following this transaction, the SVP & Treasurer owned 26,302 shares meaning that the stake was reduced by 26.51% with the 9,488-share transaction.

Gentry Jeffery S who is EVP-Operations & CSO of RJRTC at Reynolds American sold 12,288 shares at $53.49 on March 13, 2014. Following this transaction, the EVP-Operations & CSO of RJRTC owned 35,028 shares meaning that the stake was reduced by 25.97% with the 12,288-share transaction.

Caldwell Lisa J who is EVP & Chief HR Officer at Reynolds American sold 14,095 shares at $53.48 on March 13, 2014. Following this transaction, the EVP & Chief HR Officer owned 34,847 shares meaning that the stake was reduced by 28.8% with the 14,095-share transaction.

Delen Daniel M who is President & CEO at Reynolds American sold 50,319 shares at $53.49 on March 13, 2014. Following this transaction, the President & CEO owned 181,771 shares meaning that the stake was reduced by 21.68% with the 50,319-share transaction.

Smothers Frederick W who is SVP & Chief Accounting Officer at Reynolds American sold 10,353 shares at $53.49 on March 13, 2014. Following this transaction, the SVP & Chief Accounting Officer owned 15,533 shares meaning that the stake was reduced by 39.99% with the 10,353-share transaction.

Gilchrist Andrew D who is President & CCO of RJRT at Reynolds American sold 10,561 shares at $53.49 on March 13, 2014. Following this transaction, the President & CCO of RJRT owned 39,817 shares meaning that the stake was reduced by 20.96% with the 10,561-share transaction.

Stowe Robert D who is EVP-Trade Marketing of RJRT at Reynolds American sold 13,085 shares at $53.49 on March 13, 2014. Following this transaction, the EVP-Trade Marketing of RJRT owned 27,980 shares meaning that the stake was reduced by 31.86% with the 13,085-share transaction.

Holton Martin L. III who is EVP, Gen. Counsel & Asst. Sec at Reynolds American sold 10,390 shares at $53.49 on March 13, 2014. Following this transaction, the EVP, Gen. Counsel & Asst. Sec owned 42,899 shares meaning that the stake was reduced by 19.5% with the 10,390-share transaction.

Dunham Robert H. who is EVP - Public Affairs at Reynolds American sold 9,717 shares at $53.49 on March 13, 2014. Following this transaction, the EVP - Public Affairs owned 18,400 shares meaning that the stake was reduced by 34.56% with the 9,717-share transaction.

The shares most recently traded at $54.36, up $0.87, or 1.61% since the insider transaction. Historical insider transactions for Reynolds American go as follows:

  • 4-Week # shares sold: 158,245
  • 12-Week # shares sold: 907,226
  • 24-Week # shares sold: 2.0 million

The average volume for Reynolds American has been 2.8 million shares per day over the past 30 days. Reynolds American has a market cap of $28.6 billion and is part of the consumer goods sector and tobacco industry. Shares are up 6.54% year-to-date as of the close of trading on Friday.

Reynolds American Inc., together with its subsidiaries, manufactures and sells cigarette and other tobacco products in the United States. The company operates through RJR Tobacco, American Snuff, and Santa Fe segments. The stock currently has a dividend yield of 5.03%. The company has a P/E ratio of 17.0. Currently there are 3 analysts that rate Reynolds American a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RAI - FREE

TheStreet Quant Ratings rates Reynolds American as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Reynolds American Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Arch Capital Group (ACGL) - FREE Research Report

Hutchings W Preston who is SVP & Chief Investment Officer at Arch Capital Group sold 4,385 shares at $56.79 on March 13, 2014. Following this transaction, the SVP & Chief Investment Officer owned 95,615 shares meaning that the stake was reduced by 4.39% with the 4,385-share transaction.

The shares most recently traded at $57.23, up $0.44, or 0.77% since the insider transaction. Historical insider transactions for Arch Capital Group go as follows:

  • 4-Week # shares sold: 4,500
  • 12-Week # shares sold: 4,500
  • 24-Week # shares sold: 45,500

The average volume for Arch Capital Group has been 451,700 shares per day over the past 30 days. Arch Capital Group has a market cap of $7.6 billion and is part of the financial sector and insurance industry. Shares are down 4.86% year-to-date as of the close of trading on Friday.

Arch Capital Group Ltd., through its subsidiaries, provides insurance and reinsurance solutions worldwide. It operates in two segments, Insurance and Reinsurance. The company has a P/E ratio of 11.2. Currently there are 2 analysts that rate Arch Capital Group a buy, 1 analyst rates it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACGL - FREE

TheStreet Quant Ratings rates Arch Capital Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, increase in stock price during the past year and impressive record of earnings per share growth. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Arch Capital Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Italy Bonds Plunge, Stocks Hit 13-Month Low as Constitutional Crisis Intensifies

Italy Bonds Plunge, Stocks Hit 13-Month Low as Constitutional Crisis Intensifies

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain